Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Long-Term Deferred Tax (2023 - 2025)

Historic Long-Term Deferred Tax for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to $171.0 million.

  • Genmab A's Long-Term Deferred Tax rose 3464.57% to $171.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $171.0 million, marking a year-over-year increase of 3464.57%. This contributed to the annual value of $171.0 million for FY2025, which is 3464.57% up from last year.
  • As of Q4 2025, Genmab A's Long-Term Deferred Tax stood at $171.0 million, which was up 3464.57% from $127.0 million recorded in Q3 2025.
  • Genmab A's 5-year Long-Term Deferred Tax high stood at $171.0 million for Q4 2025, and its period low was $31.0 million during Q4 2023.
  • Its 3-year average for Long-Term Deferred Tax is $118.7 million, with a median of $127.0 million in 2024.
  • As far as peak fluctuations go, Genmab A's Long-Term Deferred Tax skyrocketed by 30967.74% in 2024, and later soared by 3464.57% in 2025.
  • Quarter analysis of 3 years shows Genmab A's Long-Term Deferred Tax stood at $31.0 million in 2023, then surged by 309.68% to $127.0 million in 2024, then skyrocketed by 34.65% to $171.0 million in 2025.
  • Its Long-Term Deferred Tax stands at $171.0 million for Q4 2025, versus $127.0 million for Q3 2025 and $127.0 million for Q2 2025.